ASH 2022 | The prognostic value of IgHV mutational status with continuous vs time-limited therapy in CLL
Adam Kittai, MD, Ohio State University, Columbus, OH, explains how the prognostic value of IgHV status changes according to the therapy used in chronic lymphocytic leukemia (CLL). While it appears that IgHV status does not have an impact in patients treated with continuous therapy, evidence suggests that it does have a prognostic value in patients treated with time-limited therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
Explore our dedicated feature on genomic testing in CLL here: http://bit.ly/403y417
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy; Astrazeneca: Consultancy, Research Funding; Beigene: Consultancy; Janssen: Consultancy.
